Home › Trials › NCT06948435

Orforglipron for lowering blood pressure in adults with hypertension and overweight or obesity

A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Once Daily in Participants With Hypertension and Obesity or Overweight: Randomized, Double-Blind, Placebo-Controlled Trials (ATTAIN-HYPERTENSION)

Phase 3 Interventional Eli Lilly and Company · NCT06948435

This will test whether orforglipron lowers blood pressure in adults with hypertension who are overweight or have obesity.

Quick facts

PhasePhase 3
Study typeInterventional
Enrollment487 (estimated)
Ages18 Years and up
SexAll
SponsorEli Lilly and Company Industry-sponsored
Locations99 sites (Phoenix, Arizona and 98 other locations)
Trial IDNCT06948435 on ClinicalTrials.gov

What this trial studies

Under the GZPL master protocol, this Phase 3 program assigns participants with hypertension and overweight or obesity to receive orforglipron or placebo and follows them for blood pressure and safety outcomes. The trial is conducted at multiple clinical sites in the United States and follows the inclusion/exclusion criteria defined in the master protocol. Key data collected include changes in office and/or ambulatory blood pressure, adverse events, and body weight. Results will determine whether orforglipron offers a safe, effective option for blood pressure control in this population.

Who should consider this trial

Good fit: Adults with diagnosed hypertension who meet the GZPL master protocol criteria and who are overweight or have obesity are the intended participants.

Not a fit: People without hypertension, with normal body weight, or those excluded by the GZPL master protocol (for example because of certain medical conditions or medications) are unlikely to benefit from joining.

Why it matters

Potential benefit: If successful, orforglipron could help lower blood pressure and potentially reduce cardiovascular risk in people with hypertension who are overweight or have obesity.

How similar studies have performed: Other GLP-1–based therapies have produced weight loss and modest blood pressure reductions, and earlier orforglipron studies have shown promising effects on weight, but its specific impact on hypertension is still being tested.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* refer to the GZPL master protocol for screening eligibility.

Exclusion Criteria:

* refer to the GZPL master protocol for screening eligibility.

Where this trial is running

Phoenix, Arizona and 98 other locations

+49 more sites — see ClinicalTrials.gov for the full list.

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions HypertensionOverweight or Obesity
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.